Earlier this summer, Jean-Charles Soria, senior vice president and head of Amgen's Oncology Therapeutic Area, and David Raben, vice president of Global Development, sat down for a Twitter Spaces live conversation on the impact of precision medicine in oncology, reflecting on recent successes and highlighting Amgen's research pursuing emerging actionable targets.
Over the past few decades, tremendous strides in genomics, proteomics and transcriptomics have enabled precision medicine to emerge as a new way of treating and customizing care for patients, accounting for more than a third of new drug approvals for four of the last five years. What makes precision medicine so meaningful and exciting as an approach is its potential to deliver improved outcomes for patients, while also minimizing toxicity given the specific responses these medicines mediate.
— David Raben, Vice President, Global Development
Listen to the full conversation below to hear their perspectives, and be sure to follow Amgen Oncology on Twitter to catch upcoming Twitter Spaces conversations.
